{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:18:36Z","timestamp":1788783516695,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":654,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"name":"CSL Behring AG, Berne, Switzerland"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.clim.2011.06.002","type":"journal-article","created":{"date-parts":[[2011,6,25]],"date-time":"2011-06-25T18:30:07Z","timestamp":1309026607000},"page":"90-102","source":"Crossref","is-referenced-by-count":111,"title":["Efficacy and safety of Hizentra\u00ae in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy"],"prefix":"10.1016","volume":"141","author":[{"given":"S.","family":"Jolles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bernatowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"de Gracia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Borte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Cristea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.H.","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.H.","family":"Belohradsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Wahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Neufang-H\u00fcber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Zenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Grimbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2011.06.002_bb0005","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJM200011023431806","article-title":"Primary immunodeficiency diseases due to defects in lymphocytes","volume":"343","author":"Buckley","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2011.06.002_bb0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2249.2003.02110.x","article-title":"Primary immunodeficiency diseases: an update","volume":"132","author":"Chapel","year":"2003","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.clim.2011.06.002_bb0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1006\/clim.1999.4725","article-title":"Common variable immunodeficiency: clinical and immunological features of 248 patients","volume":"92","author":"Cunningham-Rundles","year":"1999","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2011.06.002_bb0020","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/ACI.0b013e328314b621","article-title":"Ig beta deficiency in humans","volume":"8","author":"Lougaris","year":"2008","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2011.06.002_bb0025","series-title":"Primary Immunodeficiency Diseases: A Molecular and Genetic Approach","author":"Ochs","year":"2007"},{"key":"10.1016\/j.clim.2011.06.002_bb0030","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0140-6736(08)61199-X","article-title":"Common variable immunodeficiency: a new look at an old disease","volume":"372","author":"Park","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2011.06.002_bb0035","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jaci.2009.10.013","article-title":"Primary immunodeficiencies: 2009 update","volume":"124","author":"Notarangelo","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2011.06.002_bb0040","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1067\/mai.2002.124999","article-title":"Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency","volume":"109","author":"Busse","year":"2002","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2011.06.002_bb0045","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1160\/TH03-10-0650","article-title":"IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life","volume":"91","author":"Bussel","year":"2004","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.clim.2011.06.002_bb0050","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/pai.2009.0005","article-title":"Efficacy and safety of Privigen in children and adolescents with primary immunodeficiency","volume":"22","author":"Church","year":"2009","journal-title":"Pediatr. Asthma Allergy Immunol."},{"key":"10.1016\/j.clim.2011.06.002_bb0055","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.intimp.2004.02.011","article-title":"Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency","volume":"4","author":"de Gracia","year":"2004","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.clim.2011.06.002_bb0060","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7326\/0003-4819-135-3-200108070-00008","article-title":"The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial","volume":"135","author":"Eijkhout","year":"2001","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.clim.2011.06.002_bb0065","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0022-3476(99)70246-5","article-title":"Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients","volume":"134","author":"Quartier","year":"1999","journal-title":"J. Pediatr."},{"key":"10.1016\/j.clim.2011.06.002_bb0070","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10875-008-9231-2","article-title":"Safety and efficacy of Privigen\u00ae, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies","volume":"29","author":"Stein","year":"2009","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2011.06.002_bb0075","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.iac.2008.01.008","article-title":"Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency","volume":"28","author":"Berger","year":"2008","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"10.1016\/j.clim.2011.06.002_bb0080","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.iac.2008.07.002","article-title":"Subcutaneous administration of IgG","volume":"28","author":"Berger","year":"2008","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"10.1016\/j.clim.2011.06.002_bb0085","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0140-6736(91)90147-H","article-title":"Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion","volume":"338","author":"Gardulf","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2011.06.002_bb0090","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/01.all.0000246619.49494.41","article-title":"Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies","volume":"6","author":"Gardulf","year":"2006","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2011.06.002_bb0095","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10875-006-9002-x","article-title":"Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies\u2014a prospective, multi-national study","volume":"26","author":"Gardulf","year":"2006","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2011.06.002_bb0100","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10875-006-9021-7","article-title":"Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases","volume":"26","author":"Ochs","year":"2006","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2011.06.002_bb0105","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.biologicals.2010.11.004","article-title":"Local tolerance and stability up to 24months of a new 20% proline-stabilized polyclonal immunoglobulin for subcutaneous administration","volume":"39","author":"Maeder","year":"2011","journal-title":"Biologicals"},{"key":"10.1016\/j.clim.2011.06.002_bb0110","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.biologicals.2008.01.004","article-title":"Investigations of prion and virus safety of a new liquid IVIG product","volume":"36","author":"Stucki","year":"2008","journal-title":"Biologicals"},{"key":"10.1016\/j.clim.2011.06.002_bb0115","series-title":"Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the clinical investigation of human normal immunoglobulin for subcutaneous and intramuscular use","author":"European Agency for the Evaluation of Medicinal Products (EMEA)","year":"2002"},{"key":"10.1016\/j.clim.2011.06.002_bb0120","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s10875-010-9423-4","article-title":"Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency","volume":"30","author":"Hagan","year":"2010","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2011.06.002_bb0125","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1006\/clim.1999.4799","article-title":"Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies)","volume":"93","author":"Conley","year":"1999","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2011.06.002_bb0130","series-title":"Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency. Guidance for Industry","author":"Center for Biologics Evaluation and Research US FDA","year":"2008"},{"key":"10.1016\/j.clim.2011.06.002_bb0135","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2165\/11587030-000000000-00000","article-title":"Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency","volume":"50","author":"Wasserman","year":"2011","journal-title":"Clin. Pharmacokinetics"},{"key":"10.1016\/j.clim.2011.06.002_bb0140","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.clim.2011.06.002_bb0145","series-title":"Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the clinical investigation of human normal immunoglobulin for subcutaneous and intramuscular use","author":"European Agency for the Evaluation of Medicinal Products (EMEA)","year":"2002"},{"key":"10.1016\/j.clim.2011.06.002_bb0150","series-title":"Blood Products Advisory Committee Meeting","author":"Center for Biologics Evaluation and Research US FDA","year":"2007"},{"key":"10.1016\/j.clim.2011.06.002_bb0155","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJM198406143102404","article-title":"Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine","volume":"310","author":"Peltola","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2011.06.002_bb0160","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/01.mph.0000163214.37147.5a","article-title":"Antibody titers and immune response to diphtheria\u2013tetanus\u2013pertussis and measles\u2013mumps\u2013rubella vaccination in children treated for acute lymphoblastic leukemia","volume":"27","author":"Ercan","year":"2005","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.clim.2011.06.002_bb0165","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/ajcn\/73.5.908","article-title":"Amino acid kinetics in patients with sepsis","volume":"73","author":"Druml","year":"2001","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.clim.2011.06.002_bb0170","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1023\/A:1006678312925","article-title":"The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy","volume":"20","author":"Chapel","year":"2000","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2011.06.002_bb0175","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/j.1651-2227.2007.00485.x","article-title":"Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency","volume":"96","author":"Fasth","year":"2007","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.clim.2011.06.002_bb0180","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.jaci.2010.02.040","article-title":"Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22years","volume":"125","author":"Lucas","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2011.06.002_bb0185","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(95)90346-1","article-title":"Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs","volume":"345","author":"Gardulf","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2011.06.002_bb0190","doi-asserted-by":"crossref","first-page":"720","DOI":"10.7326\/0003-4819-118-9-199305010-00011","article-title":"New insights into common variable immunodeficiency","volume":"118","author":"Sneller","year":"1993","journal-title":"Ann. Intern. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.clim.2011.06.002_bb0195","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1365-2249.2009.04023.x","article-title":"Immunodeficiencies","volume":"158","author":"Ballow","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.clim.2011.06.002_bb0200","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clim.2010.06.012","article-title":"Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies","volume":"137","author":"Orange","year":"2010","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2011.06.002_bb0205","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S1567-5769(03)00134-6","article-title":"Comparison of the efficacy of IGIV-C, 10% (caprylate\/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial","volume":"3","author":"Roifman","year":"2003","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.clim.2011.06.002_bb0210","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1023\/B:JOCI.0000029108.18995.61","article-title":"Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases","volume":"24","author":"Berger","year":"2004","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2011.06.002_bb0215","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1023\/B:JOCI.0000025453.23817.3f","article-title":"Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases","volume":"24","author":"Ochs","year":"2004","journal-title":"J. Clin. Immunol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661611001884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661611001884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T09:29:53Z","timestamp":1560331793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661611001884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S1521661611001884"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2011.06.002","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}